OREON Life Science Launches AESSOA Lidocaine Fillerย
and Obtains European CE Certification
OREON Life Scienceโs AESSOA Lidocaine series (Shine, Global, Deep, and Ultra) has obtained the CE (Conformitรฉ Europรฉenne) mark, the European Union's conformity certification.
In the global hyaluronic acid (HA) filler market, valued at approximately 3 trillion KRW, lidocaine-type products account for a high share of 90%. As Europe is the home of fillers and holds 35% of global demand, expectations for OREON Life Science's revenue growth are high. OREON Life Science is a medical aesthetics specialist that previously launched Teosyal (TEOXANE)โone of the world's top three HA fillers alongside Restylane and Juvedermโin the Korean market. Through this, the company secured a significant market share in Korea for over 10 years. Additionally, it received much attention for launching filler products from Johnson & Johnson, which feature collagen as a primary ingredient.
Currently, OREON Life Science is expanding beyond the Korean market to supply its flagship Rainbow Lift and various mesotherapy products to over 60 countries, including Europe, the US, the Middle East, South America, and Asia. Most importantly, the company plans to accelerate its global management through the additional launch of AESSOA fillers.
AESSOA filler is a monophasic filler containing lidocaine. Despite its high hyaluronic acid content of 24mg, it is characterized by minimizing allergic side effects. As a high-purity HA product, it has drastically improved upon the chronic side effects of existing HA fillers. In Europe, it is already being called a next-generation filler that can replace top-tier products such as Juvederm and Teosyal.
Safety was further considered for AESSOA filler procedures by using the AESSOA Micro Cannula. The company stated that the fact that this product has also completed CE certification and is being launchedย
simultaneously is strengthening the AESSOA brand loyalty.
Kang Seong-hwan, Director of the Overseas Business Division at OREON Life Science, stated, "While European certification standards are becoming stricter due to the recent MDR system, the CE certification and global launch of AESSOA fillers containing lidocaine will make Korean fillers a game-changer that will soon become the mainstream in the global filler market."
He added, "Please keep an eye on the global success of AESSOA filler."
๐ https://www.gpkorea.com/news/articleView.html?idxno=77938ย
OREON Life Science Launches AESSOA Lidocaine Fillerย
and Obtains European CE Certification
OREON Life Scienceโs AESSOA Lidocaine series (Shine, Global, Deep, and Ultra) has obtained the CE (Conformitรฉ Europรฉenne) mark, the European Union's conformity certification.
In the global hyaluronic acid (HA) filler market, valued at approximately 3 trillion KRW, lidocaine-type products account for a high share of 90%. As Europe is the home of fillers and holds 35% of global demand, expectations for OREON Life Science's revenue growth are high. OREON Life Science is a medical aesthetics specialist that previously launched Teosyal (TEOXANE)โone of the world's top three HA fillers alongside Restylane and Juvedermโin the Korean market. Through this, the company secured a significant market share in Korea for over 10 years. Additionally, it received much attention for launching filler products from Johnson & Johnson, which feature collagen as a primary ingredient.
Currently, OREON Life Science is expanding beyond the Korean market to supply its flagship Rainbow Lift and various mesotherapy products to over 60 countries, including Europe, the US, the Middle East, South America, and Asia. Most importantly, the company plans to accelerate its global management through the additional launch of AESSOA fillers.
AESSOA filler is a monophasic filler containing lidocaine. Despite its high hyaluronic acid content of 24mg, it is characterized by minimizing allergic side effects. As a high-purity HA product, it has drastically improved upon the chronic side effects of existing HA fillers. In Europe, it is already being called a next-generation filler that can replace top-tier products such as Juvederm and Teosyal.
Safety was further considered for AESSOA filler procedures by using the AESSOA Micro Cannula. The company stated that the fact that this product has also completed CE certification and is being launchedย
simultaneously is strengthening the AESSOA brand loyalty.
Kang Seong-hwan, Director of the Overseas Business Division at OREON Life Science, stated, "While European certification standards are becoming stricter due to the recent MDR system, the CE certification and global launch of AESSOA fillers containing lidocaine will make Korean fillers a game-changer that will soon become the mainstream in the global filler market."
He added, "Please keep an eye on the global success of AESSOA filler."
๐ https://www.gpkorea.com/news/articleView.html?idxno=77938ย